Retatrutide: Reading the Early Triple-Receptor Trial
AXON Research Institute • AXON Peptide affiliation
Educational draft • Scientific + legal review pending
Silent film with full on-screen captions. Conceptual illustrations, not molecular structures.

Retatrutide acts at three receptor systems: GIP, GLP-1, and glucagon. The number of targets describes its design, not an automatic advantage over another medicine. Its 2023 phase two trial randomly assigned 338 adults to retatrutide or placebo. Researchers measured body-weight change and recorded safety outcomes over 48 weeks. Treated groups showed greater weight reduction. Gastrointestinal adverse events were common, and increases in heart rate were also observed during the study. This early trial helped guide further research. Comparisons with other drugs require matched clinical evidence, and a weight-loss result alone does not settle long-term benefit or safety.

END CARD
Research explained. Not medical advice. Sources and limitations in the accompanying transcript.

SOURCES
[1] Jastreboff et al. (2023): Triple-Hormone-Receptor Agonist Retatrutide for Obesity, a Phase 2 Trial
https://pubmed.ncbi.nlm.nih.gov/37366315/
Primary human randomized phase 2 trial

EVIDENCE LIMITATIONS
This episode deliberately explains the 2023 phase 2 paper, not the latest stage of development.
Do not label retatrutide currently phase 2 based on this historical study.
No cross-trial ranking or equivalence to a research product is supported.

TOPIC INVENTORY PROVENANCE (not reused audiovisual media)
Retatrutide: Reading the Early Triple-Receptor Trial